Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 20, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on March 12 and March 13, 2007:
- March 12, 2007: 3,096 Ordinary shares were sold on behalf of Bonus Investment Plan participants at GBP 14.45 per share. Additionally, 6,146 Ordinary shares were transferred to Bonus Investment Plan participants.
- March 13, 2007: 948 Ordinary shares were transferred to a participant in the Annual Investment Plan. Furthermore, 1,441 Ordinary shares were transferred to a participant in the Bonus Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J S Heslop holds an interest in the fund shares similarly to other beneficiaries.
Investor Verification Checklist
- Verify the total number of shares sold versus transferred in the SmithKline Beecham Bonus Investment Plan during the reporting period.
- Confirm the transaction price of GBP 14.45 per share against market data for March 12, 2007.
- Review the specific Disclosure Rule 3.1.4R(1)(b) requirements to ensure full compliance with the notification.
- Check subsequent filings for any additional director or connected person transactions not covered in this specific report.